CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...

Cracking the Code on Interoperability with Scalable, Vendor-Neutral Architectures Powering AI-Ready Health Systems Worldwide ...

Company Delivers Quarterly Revenue of $2.4 Million as Projected or $5.4 Million for full-year 2024Quarterly Net Loss and Earnings per Diluted Share of $5.8 Million and $7.26Quarterly Adjusted EBITDA ...

A breakthrough in respiratory diagnostics is set to transform the way serious lung conditions, such as Chronic Obstructive Pulmonary Disease (COPD), are detected and managed in the UK.

Typically, when organisations speak of supply chain transparency, they focus on the last mile: the product journey from “production to fork”, with a view to reducing energy and waste while optimising ...

The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...

BOC Sciences adds to its participation agenda the prestigious Drug Discovery Chemistry 2025 Conference (April 14-17, 2025), which will be a hybrid event taking place in San Diego, CA, and will offer ...

Saccharomyces cerevisiae, commonly known as baker's or brewer's yeast, is one of the most studied microorganisms in the realm of fermentation technology. This species of yeast has been utilized for ...

Abbott (NYSE: ABT) today announced it has received CE Mark in Europe for the Volt™ PFA System to treat patients battling atrial fibrillation (AFib). With the earlier-than-expected CE Mark, Abbott has ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...